Vyome Holdings, Inc
Vyome Holdings, Inc. is a U.S.-based clinical-stage specialty pharmaceutical company organized around a biotechnology pipeline and a legacy pharmaceutical products business. Its development programs focus on immune-inflammatory and rare diseases, including topical and ophthalmic candidates, while the pharmaceutical segment includes antifungal products and related licensing arrangements.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical and preclinical drug candidates for immune-inflammatory and rare diseases.
Legacy antifungal products and related commercial pharmaceutical operations.
Legacy licensing agreements and potential partnering arrangements around assets.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products54,6 %
- License36,6 %
- Royalty8,8 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company’s biotechnology programs are aimed at patients with serious unmet medical needs, typically accessed through physicians, specialists, and clinical trial sites rather than direct consumer channels. Its pharmaceutical segment serves healthcare providers and patients through antifungal products, with commercialization shaped by licensing relationships and specialty prescribing patterns.
They use the pipeline therapies for rare, inflammatory, or dermatologic conditions where current options are limited.
They prescribe the antifungal products and influence adoption through treatment protocols.
Investigators, sites, and enrolled patients support development of VT-1953, VT-1908, and VB-1953.
Partners such as Sun Pharma-related arrangements support legacy pharmaceutical economics.
Strategia
The company’s strategy centers on advancing its lead clinical and preclinical programs toward regulatory milestones while preserving access to external capital. It also seeks to use collaborations, licensing, and financing tools to support development of its pipeline and legacy pharmaceutical assets.
This is the lead program and the most advanced path to a potential commercial asset.
Diversifies the pipeline across multiple specialty indications and reduces single-asset dependence.
Clinical development requires capital and the company expects to rely on financing and collaborations.
Maantiede
Q2/2025Vyome Holdings is based in the United States, with a reported operating footprint spanning Cambridge, Massachusetts, Princeton, New Jersey, and New Delhi, India. The U.S.-India structure matters because the company combines U.S.-based clinical and corporate functions with Indian innovation and development capabilities.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Vyome’s business depends on successful clinical development, regulatory clearance, and the ability to finance a pipeline that has no approved biotechnology products. The company also faces execution risk from its dual-segment structure, where legacy pharmaceutical revenue is separate from development spending, and from the uncertainty of raising capital on acceptable terms.
Pipeline value depends on positive preclinical and clinical results and timely advancement.
The company expects to fund operations through equity, debt, and collaborations until product revenue exists.
Kohdistuu: Corporate funding needs
Drug development requires FDA alignment on protocols, approvals, and labeling.
Kohdistuu: Pivotal trial and pre-IND programs
Antifungal products and licensing arrangements may not generate enough scale to support the business.
Kohdistuu: Pharmaceutical segment
Kirjanpito
Harkinnanvaraiset erätThe company elected fair value accounting, so changes in valuation can flow through earnings.
Vaikutus: Non-cash income or expense volatility
Embedded conversion or option features may need separate fair value measurement.
Vaikutus: Can materially affect reported results period to period
Employee and consultant awards are common in development-stage biotech and affect operating expense.
Vaikutus: Dilution and expense recognition
The merger and related recapitalization require careful purchase accounting and equity presentation.
Vaikutus: Affects balance sheet and comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Päivitetty: 24.9.2026